Faruqi & Faruqi, LLP: Investigating Potential Claims Against Geron Corporation
Faruqi & Faruqi, LLP, a renowned securities law firm, is currently examining potential claims against Geron Corporation (Geron or the Company) (NASDAQ: GERN) following significant financial losses between February 28, 2024, and February 25, 2025. The firm encourages investors who have incurred losses exceeding $100,000 during this period to contact securities litigation partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Background
Geron is a biotechnology company focused on the development and commercialization of therapeutics for aging and age-related diseases. The Company’s primary product, Imetelstat, is an investigational therapy for myelofibrosis and beta-thalassemia. However, during the aforementioned period, Geron faced numerous challenges that negatively impacted its stock price.
Investigations and Class Action Lawsuit
Faruqi & Faruqi, LLP, has initiated an investigation into potential securities laws violations by Geron, and a federal securities class action lawsuit has been filed against the Company. The complaint alleges that Geron made false and misleading statements regarding its business, operations, and financial condition, which artificially inflated the stock price.
Impact on Individual Investors
If you are an investor in Geron and have suffered losses exceeding $100,000 between February 28, 2024, and February 25, 2025, you may be eligible to join the class action lawsuit. Contacting Faruqi & Faruqi partner Josh Wilson directly can help you understand your legal rights and potential remedies.
Global Implications
The implications of this investigation and class action lawsuit extend beyond Geron’s investors. It highlights the importance of transparency and truthfulness in corporate reporting. Biotech companies, in particular, face unique challenges in communicating their progress and setbacks to the public. This case serves as a reminder that accurate and timely disclosures are crucial for maintaining investor confidence and trust.
Conclusion
Investors who have experienced significant losses in Geron between February 28, 2024, and February 25, 2025, are encouraged to contact Faruqi & Faruqi partner Josh Wilson for a confidential discussion regarding their legal rights and potential remedies. The ongoing investigation and class action lawsuit against Geron underscore the importance of transparency and truthfulness in corporate reporting, emphasizing the need for continued diligence and vigilance among investors.
- Faruqi & Faruqi, LLP, is investigating potential claims against Geron Corporation.
- A federal securities class action lawsuit has been filed against the Company.
- Investors who suffered losses exceeding $100,000 are encouraged to contact Faruqi & Faruqi partner Josh Wilson.
- The case highlights the importance of transparency and truthfulness in corporate reporting.
